Adherence to Biologic and Conventional Disease Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis
نویسندگان
چکیده
منابع مشابه
Bone mineral density changes during treatment of rheumatoid arthritis with disease-modifying-anti-rheumatic drugs
Background: Bone mineral density (BMD) changes during the course of rheumatoid arthritis (RA). The present study was designed to investigate the status of BMD in patients with RA treated with anti-rheumatic drugs. Methods: BMD at the femoral neck (FN-BMD) and lumbar spine (LS-BMD) were measured by dual energy x-ray absorptiometry (DXA) method using Norland densitometer. Disease activity (DA) wa...
متن کاملOptimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs.
Conventional DMARDs such as MTX are the mainstay of treatment for patients with RA. However, failure to achieve adequate disease control in many patients, even with combination therapy, has spurred the development of agents that target various immune mediators involved in the disease process. In the past decade, biologic agents have proved viable as alternative or add-on therapy to DMARDs in pa...
متن کاملbone mineral density changes during treatment of rheumatoid arthritis with disease-modifying-anti-rheumatic drugs
background: bone mineral density (bmd) changes during the course of rheumatoid arthritis (ra). the present study was designed to investigate the status of bmd in patients with ra treated with anti-rheumatic drugs. methods: bmd at the femoral neck (fn-bmd) and lumbar spine (ls-bmd) were measured by dual energy x-ray absorptiometry (dxa) method using norland densitometer. disease activity (da) wa...
متن کاملResponse to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid Arthritis
INTRODUCTION The aim of this study was to compare the response between subsequent use of anti-tumor necrosis factor α (anti-TNF) agents and biologic disease-modifying anti-rheumatic drugs (bDMARD) with other mechanism of action (MOA) in rheumatoid arthritis (RA) patients with history of anti-TNF treatment as their first bDMARD. METHODS A retrospective chart review was conducted at eight commu...
متن کاملSafety, cost and effectiveness issues with disease modifying anti-rheumatic drugs in rheumatoid arthritis.
Safety, cost, and eVectiveness studies are critically important for definitive assessment of disease modifying drugs (DMARDs), particularly when new mechanisms of drug action are likely to be present. This requires post-marketing surveillance, as these dimensions cannot be adequately assessed in pre-marketing studies. “Post-marketing surveillance”, in our definition, is “the asking and answerin...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2018
ISSN: 1098-3015
DOI: 10.1016/j.jval.2018.04.1362